Phase I Study of BL22, A Recombinant Immunotoxin for Chronic Lymphocytic Leukemia and CD22+ Lymphomas.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs CAT 3888 (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 21 Jun 2010 Trial sponsor and lead centre (MedImmune) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Trial sponsor and lead centre (MedImmune) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.